Adoptive cell therapy for cancer treatment

Du, Shi; Yan, Jiajie; Xue, Yonger; Zhong, Yichen; Dong, Yizhou

doi:10.1002/exp.20210058

Cited by 20 publications

(1 citation statement)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 However, limited cure options are available for the sustained, recurrent, and transferred cases, leading to a subsequent poor prognosis. [4][5][6] For patients with unresectable CC, cisplatin (CDDP) is the most common chemical therapeutic option. [7][8][9] Unfortunately, CDDP did not benefit pelvic control or survival at the advanced stage of CC treatment.…”

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Guo,

Huang,

Wang

et al. 2023

IJN

View full text Add to dashboard Cite

Cervical cancer (CC) is a highly vascularized tumor with abundant abnormal blood vessel, which could be targeted by therapeutic strategies. Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential as nano vascular disrupting agents (VDAs) in the realm of synergistic cancer therapy. Methods: In this study, we investigated the nanocharacteristics of CB-NPs, focusing on active pharmaceutical ingredients (API), as well as lyophilized samples combining API with protective agents (PAs). The in vivo efficacy of final sample (API + PAs) was evaluated. Results:The assembled sphere of API with complex core and thin-shell structure was confirmed. PAs were found to significantly influence in vivo efficacy. Collaborative efforts between API and PAs, namely mannitol and lactose, resulted in the most promising lyophilized sample, ie, the final sample (FS2) for CC therapy. Impressively, FS2 demonstrated an exceptional 100% cure rate on the CC U14-bearing mice model. Conclusion: FS2 has provided significant insights for cervical cancer therapy. It is also crucial to develop a comprehensive evaluation strategy for the formulation of nanomedicine, which has the potential to serve as a guideline for future clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Guo,

Huang,

Wang

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

Nano‐Engineered Magnesium Implants for Magnetothermal Enhanced Pyroptosis to Boost Immunotherapy

Han,

Sun,

Yang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading contributors to cancer‐related death because the immunosuppressive tumor microenvironment (TME) limits its therapeutic efficacy. Gasdermin (GSDM)‐mediated pyroptosis is a new programmed cell death that can boost antitumor immune responses. However, inducing efficient pyroptosis to reverse the immunosuppressive TME is challenging. Herein, layered double hydroxide‐coated magnesium (Zn‐LDH@Mg) implants are designed and constructed as alternating magnetic field (AMF)‐activated pyroptosis inducers to induce highly effective pyroptosis in cancer cells. The powerful eddy‐thermal effects of Zn‐LDH@Mg implants markedly amplify pyroptosis in malignant cells through the Caspase‐1/GSDMD‐dependent canonical pathway. Moreover, Mg2+ and pyroptosis synergistically activate T cells (especially CD8+ T cells) and enhance the infiltration of immune‐supportive cells. This innovative strategy not only significantly suppresses the proliferation of the primary tumor but also stimulates the immune response to further enhance the efficacy of immune checkpoint inhibitors and impede the progression of distant tumors. This work not only emphasizes the importance of surface engineering strategies for the preparation of novel pyroptosis inducers but also highlights the effectiveness of the strategy in reversing the immunosuppressive TME to enhance immunotherapy, providing a new approach for the rational design of bioactive materials to increase the efficacy of immunotherapy.

show abstract

Extracellular Vesicle‐Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC‐Mediated Tumor Immunotherapy

He,

Li,

Dang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The development of nanovaccines capable of eliciting tumor‐specific immune responses holds significant promise for tumor immunotherapy. However, many nanovaccine designs rely heavily on incorporating multiple adjuvants and carriers, increasing the biological hazards associated with these additional components. Here, this work introduces novel flexible nanocapsules (OVAnano) designed to mimic extracellular vesicles, primarily using the ovalbumin antigen and minimal polyethylenimine adjuvant components. These results show that the biomimetic flexible structure of OVAnano facilitates enhanced antigen uptake by dendritic cells (DCs), leading to efficient antigen and adjuvant release into the cytosol via endosomal escape, and ultimately, successful antigen cross‐presentation by DCs. Furthermore, OVAnano modulates the intracellular nuclear factor kappa‐B (NF‐κB) signaling pathway, promoting DC maturation. The highly purified antigens in OVAnano demonstrate remarkable antigen‐specific immunogenicity, triggering strong antitumor immune responses mediated by DCs. Therapeutic tumor vaccination studies have also shown that OVAnano administration effectively suppresses tumor growth in mice by inducing immune responses from CD8+ and CD4+ T cells targeting specific antigens, reducing immunosuppression by regulatory T cells, and boosting the populations of effector memory T cells. These findings underscore that the simple yet potent strategy of employing minimal flexible nanocapsules markedly enhances DC‐mediated antitumor immunotherapy, offering promising avenues for future clinical applications.

show abstract

Adoptive cell therapy for cancer treatment

Cited by 20 publications

References 138 publications

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy

Nano‐Engineered Magnesium Implants for Magnetothermal Enhanced Pyroptosis to Boost Immunotherapy

Extracellular Vesicle‐Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC‐Mediated Tumor Immunotherapy

Contact Info

Product

Resources

About